Project description
Real-time monitoring of cardiac function following open-heart surgery
Open-heart surgery is a high-risk operation where the chest is cut open to expose the heart. It requires continuous monitoring of cardiac function to identify potential complications, but existing technologies fail to provide real-time and accurate data during and after surgery. The EU-funded SAMBAfun project addresses this unmet medical need through a novel sensor that can be incorporated into existing temporary epicardial pacemaker leads. In a nutshell, the innovation allows measurement of the velocity of each cardiac contraction, which is vital for monitoring cardiac function. The data appears on a monitor and can alert medical staff of any complication following cardiac surgery.
Objective
In patients undergoing open-heart surgeries, perioperative cardiac monitoring is used to track the functioning of the heart and identify complications. However, myocardial failure and other severe complications can escape detection using current monitoring technologies, given the trade-offs between invasiveness, real time measurements, accessibility and accuracy of data. Given the high-risk profile of these surgeries, failure to timely detect complications leads to increased mortality and morbidity, which in turn results in increased hospitalization costs and lower quality of life for the affected patients.
For effective cardiac monitoring, surgeons need real time data, 24h continuous monitoring during and post-surgery, and an accurate biosignal marker that can be trusted for immediate detection and assessment of cardiac events. No current technology enables this with low invasiveness and risk.
Cardiaccs (SME) and Osypka (SME) will bring to market a patented solution that involves adding a 3-axis accelerometer to a standard epicardial pace lead, which is routinely used for most cardiac surgical patients, to assess cardiac motion and contractility in real time, both during and after surgery – and up to 7 days. Data from CardiSense will appear on a monitor and an alert function will let surgeons and nurses know as soon as a complication is picked-up on the continuously analysed data.
SAMBAfun brings together 2 SMEs with complementary know-how, IPR and value chain positions. Cardiaccs patented the concept, whereas Osypka has 40 years of experience in developing cardiac pace leads. Osypka dominates the German market and has extensive ties to global distributors. Three leading research hospitals (Oslo, Aarhus and Berlin) will demonstrate the latest advances in this device, provide Key Opinion Leader input and contribute with multi-market, highly credible data for regulatory certification and health economic models to support reimbursement applications in all markets.
Fields of science
- social sciencessociologydemographymortality
- medical and health sciencesclinical medicinesurgery
- natural scienceschemical sciencesinorganic chemistrypost-transition metals
- medical and health sciencesclinical medicinecardiology
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistancemultidrug resistance
Keywords
Programme(s)
Funding Scheme
IA - Innovation actionCoordinator
0458 Oslo
Norway
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.